Immune Reconstitution Inflammatory Syndrome in Natalizumab-Associated PML
Neurol 77:1061-1067,1033, Tan, I.L.,et al, 2011
Relapse Management in Multiple Sclerosis
The Neurologist 15:1-5, Thrower,B.W., 2009
Intravenous Immunoglobulin in Autoimmune Neuromuscular Diseases
JAMA 291:2367-2375, Dalakas,M.C., 2004
European Study on Intravenous Immunoglobulin in Multiple Sclerosis
Arch Neurol 61:1409-1412, Filippi,M.,et al, 2004
Intravenous Immunoglobulin Treatment Following the First Demyelinating Event Suggestive of Multiple Sclerosis
Archn Neurol 61:1515-1520, Achiron,A.,et al, 2004
Intravenous Immunoglobulin in Secondary Progressive Multiple Sclerosis: Randomised Placebo-Controlled Trial
Lancet 364:1149-1156, Hommes,O.R.,et al, 2004
IV Immunoglobulins as Add-on Treatment to Methylprednisolone for Acute Relapses in MS
Neurol 63:2028-2033, Sorensen,P.S.,et al, 2004
Disease Modifying Therapies in Multiple Sclerosis
Neurol 58:169-178, Goodin,D.S.,et al, 2002
Plasma Exchange for Severe Attacks of CNS: Demyelination: Predictors of Response
Neurol 58:143-146, Keegan,M.,et al, 2002
Systematic Review of Immunomodulatory Drugs for the Treatment of People with Multiple Sclerosis: Is There Good Quality Evidence on Effectiveness and Cost?
JNNP 70:574-579, Bryan,J.,et al, 2001
Intravenous Immunoglobulin Treatment in Neurologic Disorders
Arch Neurol 56:1025-1027,1032, Sorensen,P.S., 1999
Is the Routine Use of Intravenous Immunoglobulin Treatment in Neurologic Disorders Justified?
Arch Neurol 56:1028-1032, Karussis,D.&Abramsky,O., 1999
Intravenous Immunoglobulin Treatment in Multiple Sclerosis, Effect on Relapses
Neurol 50:398-402, Achiron,A.,et al, 1998
Optic Neuritis, Prognosis for Multiple Sclerosis from MRI, CSF, and HLA Findings
Neurol 50:708-714, Soderstrom,M.,et al, 1998
Intravenous Immunoglobulin G Reduces MRI Activity in Relapsing Multiple Sclerosis
Neurol 50:1273-1281, Sorensen,P.S.,et al, 1998
The Predictive Value of CSF Ologoclonal Banding for MS 5 Years After Optic Neuritis
Neurol 51:885-887, Cole,S.R.,et al, 1998
Randomised Placebo-Controlled Trial of Monthly IVIg Therapy in Relapsing-Remitting MS
Lancet 349:589-593, 5861997., Fazekas,F.,et al, 1997
Correlation of Clinical, Magnetic Resonance Imaging, and Cerebrospinal Fluid Findings in Optic Neuritis
Ann Neurol 41:392-398, Jacobs,L.D.,et al, 1997
Management of Multiple Sclerosis
NEJM 337:1604-1611, Rudick,R.A.,et al, 1997
Open Controlled Therapeutic Trial of Intravenous Immune Globulin in Relapsing-Remitting Multiple Sclerosis
Arch Neurol 49:1233-1236, Achiron,A.,et al, 1992
Cerebrospinal Fluid Immunoglogulins & MS, Correspondence MRI & Visually Evoked Potential Changes
Arch Neurol 46:367-371, Miller,F.A.J.,et al, 1989
The Relationship Between Levels of CSF Myelin Basic Protein & IgG Measurements in Patients with Multiple Sclerosis
Ann Neurol 17:475-480, Warren,K.G.,et al, 1985
New Diagnostic Criteria for Multiple Sclerosis:Guidelines for Research Protocols
Neurol 13:227-231, Poser,C.M.,et al, 1983
Correlation of Isotopic Cisternographic Patterns in Multiple Sclerosis with CSF IgG Values
Ann Neurol 12:486-489, Bartolini,S.,et al, 1982
The Use & Abuse of the Cerebrospinal Fluid IgG Profile in the Adult:A Practical Evaluation
Ann Neurol 8:426-434, Hershey,L.A.,et al, 1980
Multiple Sclerosis de Novo CNS IgG Synthesis:Effect of ACTH & Corticosteroids
Neurol 30:1155-1162, Tourtellotte,W.W.,et al, 1980
Cerebrospinal Fluid IgG, IgA, IgM, IgD, & IgE Levels in Central Nervous System Disorders
Neurol 28:988-990, Nerenberg,S.T.,et al, 1978
Multiple Sclerosis:Diagnostic Usefulness of Cerebrospinal Fluid
Ann Neurol 2:425, Johnson,K.,et al, 1977
Surgical Lesions Misdiagnosed as Multiple Sclerosis-Indication for Contrast Study
Milit Med 141:378, Finelli,P.F., 1976
A Blood Test for Multiple Sclerosis Based on the Adherence of Lymphocytes to Measles-Infected Cells
NEJM 294:1423, Levy,N.L.,et al, 1976
Herpes Simplex & the Human Nervous System
Milit Med 140:765, Finelli,P.F., 1975
Optic Neuritis & Multiple Sclerosis
NEJM 280:1140, Arnason,B.G.W., 1973
Cerebrospinal Fluid Levels of IgG, IgA, & IgM in Neurologic Diseases
Neurol 23:953, Savory,J., 1973
Multiple Sclerosis Associated with Defects in Neuromuscular Transmission
JNNP 35:385, Patten,B.M.,et al, 1972
Adverse Events Associated with Disease-Modifying Drugs for Multiple Sclerosis
Neurol 102:e208006, Ng, HS.,et al, 2024
Overlapping Anti-NMDAR Encephalitis and Multiple Sclerosis: A Case Report and Literature Review
Front Immunol doi:10.3389/Fimmun.2023.1088801, Liu,P.,et al, 2023
Drug-Related Demyelinating Syndromes: Understanding Risk Factors, Pathophysiological Mechanisms and Magnetic Resonance Imaging Findings
Mult Scler Rel Dis 55:103146, Rimkus, C.M.,et al, 2021
Infection Risks Among Patients with Multiple Sclerosis Treated with Fingolimod, Natalizumab, Rituximab, and Injectable Therapies
JAMA Neurol 77:184-191, Luna, G.,et al, 2020
Initial Highly Effective Therapy for MS
Neurol 95:1114-1116, Wallin, M.T., 2020
Effect of Nonmyeloablative Hematopoietic Stem Cell Transplantation vs Continued Disease-Modifying Therapy on Disease Progression in Patients with Relapsing-Remitting Multiple Sclerosis
JAMA 32:165-174,153, Burt, R.K.,et al, 2019
Drug Reaction with Eosinophilia and Systemic Symptoms after Daclizamub Therapy
Neurol 91:e359-e363, Rauer,S.,et al, 2018
Natalizumab-Associated PML
Neurol 88:1197-1205, Schwab, N.,et al, 2017
Fulminant Central Nervous System Nocardiosis in a Patient Treated with Alemtuzumab for Relapsing-Remitting Multiple Sclerosis
JAMA Neurol 73:757-759, Penkert, H.,et al, 2016
Reactivation of Herpesvirus under Fingolimod: A Case of Severe Herpes Simplex Encephalitis
Neurol 84:2377-2378, Pfender, N.,et al, 2015
Cryptococcal Meningoencephalitis in a Patient with Multiple Sclerosis Treated with Fingolimod
JAMA Neurol 72:1203-1205, Zhan, Y.,et al, 2015
Mycophenolate Mofetil in Multiple Sclerosis: A Multicentre Retrospective Study on 344 Patients
JNNP 85:279-283,246, Michel, L.,et al, 2014
The Etiology of Ring Lesions on Diffusion-Weighted Imaging
NeuroRadiol J 27:280-287, Finelli, P. & Foxman, E.B., 2014
Risk of Natalizumab-Associated Progressive Multifocal Leukoencephalopathy
NEJM 366:1870-1880,1938, Bloomgren, G.,et al, 2012
Tumefactive Multiple Sclerosis Lesions under Fingolimod Treatment
Neurol 79:2000-2002,1942, Visser, F.,et al, 2012